B. Cell Biology Stem Cell [B. Cell Biology/Stem Cell] B-1 Pathological Mechanism of a Constitutively Active Form of Stromal Interaction Molecule 1 (STIM1) in Skeletal Muscle Ji Hee Park¹,², Seung Yeon Jeong¹,², Jun Hee Choi¹,², Eun Hui Lee¹,²* ¹Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea, ²Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea STIM1 is the main protein that, along with Orai1, mediates SOCE in skeletal muscle. Abnormal SOCE due to mutations in STIM1 is one of the
causes of human skeletal muscle diseases. STIM1-R304Q has been found in human patients with skeletal muscle phenotypes such as muscle weakness, myalgia, muscle stiffness, and contracture. However, the pathological mechanism(s) of STIM1-R304Q in skeletal muscle have not been well studied. To examine the pathological mechanism(s) of STIM1-R304Q in skeletal muscle, STIM1-R304Q was expressed in mouse primary skeletal myotubes, and the properties of the skeletal myotubes were examined. STIM1-R304Q did not interfere with the terminal differentiation of skeletal myoblasts to myotubes and retained the
ability of STIM1 to attenuate DHPR activity. STIM1-R304Q induced hyper-SOCE (that exceeded the SOCE by wild-type STIM1) by affecting both the amplitude and the onset rate of SOCE. Unlike that by wild-type STIM1, hyper-SOCE by STIM1-R304Q contributed to a disturbance in Ca2+ distribution between the cytosol and the SR. Moreover, the hyper-SOCE and the high cytosolic Ca2+ level induced by STIM1-R304Q involve changes in mitochondrial shape. Therefore, a series of these cellular defects induced by STIM1-R304Q could induce deleterious skeletal muscle phenotypes in human patients carrying
STIM1-R304Q. Pathological mechanism of a constitutively active form of stromal interaction molecule 1 in skeletal muscle Ji Hee Park 1,2,† , Seung Yeon Jeong 1,2,† , Jun Hee Choi 1,2 and Eun Hui Lee 1,2,* 1 Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea 2 Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea † Equal contribution * correspondence (ehui@catholic.ac.kr) A B S T RACT R E S ULTS Stromal interaction molecule 1 (STIM1) is the main protein that, along with Orai1, mediates
store- Control wt STIM1 operated Ca 2+ entry (SOCE) in skeletal muscle. Abnormal SOCE due to mutations in STIM1 is one 1.00 ± 0.29 1.07 ± 0.35 STIM1-R304Q 8.00 ± 0.27 * ,# of the causes of human skeletal muscle diseases. STIM1-R304Q (a constitutively active form of Basal SOCE (47) (51) (50) STIM1) has been found in human patients with skeletal muscle phenotypes such as muscle ▲ Supplementary Table S1. Extracellular Ca 2+ entry weakness, myalgia, muscle stiffness, and contracture. However, the pathological mechanism(s) of without the depletion of the SR in wtSTIM1 or STIM1- STIM1-R304Q in
skeletal muscle have not been well studied. To examine the pathological R304Q-expressing myotubes. Extracellular Ca 2+ entry without the depletion of the SR (i.e., basal SOCE) in mechanism(s) of STIM1- R304Q in skeletal muscle, STIM1-R304Q was expressed in mouse wtSTIM1- or STIM1-R304Q-expressing myotubes was primary skeletal myotubes, and the properties of the skeletal myotubes were examined using single- measured. The myotubes were incubated with the imaging solution without Ca 2+ (0 mM) for 15 min, and extracellular myotube Ca 2+ imaging, transmission electron microscopy (TEM), and
biochemical approaches. Ca 2+ (2 mM) was then applied to the myotubes to induce STIM1-R304Q did not interfere with the terminal differentiation of skeletal myoblasts to myotubes basal SOCE. The experimental mean values were normalized to the mean values of the control (for the area and retained the ability of STIM1 to attenuate dihydropyridine receptor (DHPR) activity. STIM1- under the peaks of basal SOCE) and the values are presented R304Q induced hyper-SOCE (that exceeded the SOCE by wild-type STIM1) by affecting both the as the mean ± SE for the number of myotubes shown in parentheses.
*Significant difference compared with control amplitude and the onset rate of SOCE. Unlike that by wild-type STIM1, hyper-SOCE by STIM1- (p < 0.05). # Significant difference compared with wtSTIM1 R304Q contributed to a disturbance in Ca 2+ distribution between the cytosol and the sarcoplasmic (p < 0.05). reticulum (SR) (high Ca 2+ in the cytosol and low Ca 2+ in the SR). Moreover, the hyper-SOCE and the high cytosolic Ca 2+ level induced by STIM1-R304Q involve changes in mitochondrial shape. Control wtSTIM1 Therefore, a series of these cellular defects induced by STIM1-R304Q could induce
deleterious ▲ Figure 1. Schematic of the primary structure of STIM1, the expression of RyR1 1.00 ± 0.00 1.01 ± 0.02 STIM1-R304Q 1.01 ± 0.02 skeletal muscle phenotypes in human patients carrying STIM1-R304Q. wtSTIM1 or STIM1-R304Q in mouse primary skeletal myotubes, and myotube DHPR 1.00 ± 0.00 1.05 ± 0.06 1.03 ± 0.04 width. (A) the location of R304 is indicated. Numbers indicate the amino acid SERCA1a 1.00 ± 0.00 1.01 ± 0.02 1.01 ± 0.03 sequence. Each domain of STIM1 is present [7]. S, signal peptide; cEF, canonical EF- Orai1 1.00 ± 0.00 1.02 ± 0.04 0.76 ± 0.04 * ,# hand; hEF, nonfunctional
hidden EF-hand; SAM, sterile α-motif; T, transmembrane STIM1 1.00 ± 0.00 1.01 ± 0.05 1.00 ± 0.03 domain; CC, coiled-coil domian; CAD/SOAR, Ca 2+ release-activated Ca 2+ -activating ▲ Supplementary Table S2. Expression levels of I N T R O DUC TI O N domain/STIM1-Orai1-activating region; PS, proline/serine-rich domian; and L, lysin- proteins that mediate Ca 2+ movements in wtSTIM1 or rich domain; (B) mouse primary skeletal myotubes that were transfected with cDNA of empty vector (control), wtSTIM1, or STIM1-R304Q were stained with anti-GFP STIM1-R304Q-expressing myotubes. The lysate of wtSTIM1-
or STIM1-R304Q-expressing myotubes was (for detecting CFP or CFP-tagged proteins) and Cy3-conjugated secondary antibodies. Initiation of skeletal muscle contraction is mediated by excitation–contraction (EC) coupling [1–3]. In short, The bar represents 100µm; (C) myotube width was measured. The mean values of subjected to immunoblot assays with one of the antibodies against five proteins that mediate intracellular Ca 2+ -release t-tubule membrane depolarization serially activates (1) the dihydropyridine receptor (DHPR) on the t-tubule each normalized to the mean value of the control are
summarized as histograms (Table or SOCE in skeletal muscle. α-actin was used as a loading 1). membrane, (2) the ryanodine receptor 1 (RyR1) on the sarcoplasmic reticulum (SR) membrane (by physical ▲ Figure 2. Ca 2+ entry through the SOCE mechanism and intracellular control. Three independent experiments were conducted per each protein. *Significant difference compared with the interactions between active DHPR and RyR1), and (3) Ca 2+ release from the SR to the cytosol through active Ca 2+ release. (A) Ca 2+ of the SR in wtSTIM1- or STIM1-R304Q-expressing control (p < 0.05). # Significant
difference compared with RyR1. Finally, Ca 2+ in the cytosol turns on a series of contractile proteins by binding to troponin C. Therefore, myotubes was depleted by treatment with thapsigargin (2.5 µM) in the absence wtSTIM1 (p < 0.05). of extracellular Ca 2+ , and extracellular Ca 2+ (2 mM) was then applied to the the change in intracellular Ca 2+ levels is a messenger event that connects membrane depolarization to muscle myotubes to induce SOCE. The experimental mean values were normalized to contraction during skeletal muscle contraction. In addition to the initiation of skeletal muscle
contraction, the the mean values of the control (for the area under the peaks on the left-hand side and for the slope in the rising phase of SOCE on the right-hand side, Table maintenance of high cytosolic Ca 2+ levels during skeletal muscle contractions, such as long periods or 1). KCl (B) or caffeine (C) was applied to the myotubes, and intracellular Ca 2+ Control wtSTIM1 STIM1-R304Q repetitive contractions, is another important issue to understand skeletal muscle contraction. release from the SR to the cytosol through RyR1 was measured. The JP1 1.00 ± 0.00 0.99 ± 0.04 1.03 ± 0.04
experimental values were normalized to the mean values of the control (Table JP2 1.00 ± 0.00 0.99 ± 0.03 1.03 ± 0.05 Extracellular Ca 2+ entry contributes to the maintenance of high cytosolic Ca 2+ levels during skeletal muscle 1). A representative trace for each group is shown (A-C). *Significant TRPC1 1.00 ± 0.00 1.04 ± 0.06 1.58 ± 0.12 * ,# contractions, and store-operated Ca 2+ entry (SOCE) is the main extracellular Ca 2+ entry method in skeletal difference compared with the control (p < 0.05). # Significant difference TRPC3 1.00 ± 0.00 1.03 ± 0.06 1.05 ± 0.06 compared with wtSTIM1 (p
<0.05). muscle [2,3]. Orai1 (a Ca 2+ entry channel) on the t-tubule membrane and stromal interaction molecule 1 ▲ Supplementary Table S3. Expression levels of JP1, (STIM1, a Ca 2+ sensor) on the SR membrane are the main SOCE-mediating proteins in skeletal muscle by the JP2, TRPC1, or TRPC3 in wtSTIM1 or STIM1-R304Q- expressing myotubes. The lysate of wtSTIM1- or STIM1- formation of puncta (i.e., oligomeric complexes of STIM1s and Orai1s). Various mutations in STIM1 (at H72, R304Q-expressing myotubes was subjected to immunoblot N80, G81, D84, S88, L92, L96, Y98, F108, H109, I115, E136X, P165,
L251, R304, R426, R429, and I484) assays with one of the antibodies against JP1, JP2, TRPC1, have been reported [4–8]. Patients with skeletal muscle diseases involving STIM1 mutations have also been or TRPC3. α-actin was used as a loading control. Three independent experiments were conducted per each protein. reported [2–8]. For example, congenital myopathies have been associated with E136X; muscular hypotonia *Significant difference compared with the control (p < 0.05). with R429C; tubular aggregate myopathy with N80T, G81D, L96V, F108I, H109R, I115F, or I484R; skeletal # Significant
difference compared with wtSTIM1 (p < 0.05). muscle atrophy and progressive muscle weaknesses with H72Q, D84G, H109N, H109R, or R304W. STIM1 R304 is located in a coiled-coil domain of STIM1, and human patients with substitution of the arginine at residue 304 by tryptophan (STIM1-R304W, a constitutively active form of STIM1) show Stormorken syndrome, which is a multisystemic disease characterized by skeletal muscle phenotypes, including tubular aggregate myopathy, muscle spasms, muscle weakness, atrophy, lack of endurance, and hematological phenotypes [5,9–11]. Studies on STIM1-R304W with cells
from patients with Stormorken syndrome or model mice carrying STIM1-R304W suggest that excessive SOCE is a cause of multisystemic defects caused by STIM1-R304W [4,5,12,13]. ▲ Figure 3. Cytosolic Ca 2+ levels, the amount of Ca 2+ releasable from the SR, and expression levels of Ca 2+ movement-mediating proteins. (A) cytosolic Ca 2+ levels at Interestingly, patients with substitution of the arginine at residue 304 by the less hydrophobic glutamine rest were measured in wtSTIM1- or STIM1-R304Q-expressing myotubes, and the ▲ Figure 4. Shapes of mitochondria. (A) mitochondria of wtSTIM1- or
(STIM1-R304Q, another constitutively active form of STIM1) rather than tryptophan (STIM1-R304W) mean values are summarized as histograms (Table 1); (B) amount of Ca 2+ releasable STIM1-R304Q-expessing myotubes were observed using TEM. Mitochondria from the SR to the cytosol was measured in the myotubes by treatment with manifest a milder and lesser deleterious clinical phenotype of Stormorken syndrome, such as muscle thapsigargin (2.5 µM) in the absence of extracellular Ca 2+ . The mean values of each with concentrically laminated bodies (enlarged images) or long mitochondria (indicated by
arrows) were found in STIM1-R304Q-expressing myotubes. The weakness, myalgia, m
